{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:41:36Z","timestamp":1792215696372,"version":"4.4.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.amjmed.2026.09.018","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:49:38Z","timestamp":1790434178000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A new class of drugs approved in the United States for hypertension: Aldosterone synthase inhibitors"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4062-0143","authenticated-orcid":false,"given":"C. Venkata S.","family":"Ram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-1718","authenticated-orcid":false,"given":"V.K.","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10304","key":"10.1016\/j.amjmed.2026.09.018_bib0001","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.amjmed.2026.09.018_bib0002","first-page":"e212","volume":"82","author":"Jones","year":"2025","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.amjmed.2026.09.018_bib0003","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.amjmed.2026.09.018_bib0004","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70080","article-title":"Blood pressure-lowering effects of aldosterone synthase inhibitors-A systematic review","volume":"137","author":"Rasmussen","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.amjmed.2026.09.018_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.amjmed.2026.09.018_bib0006","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an international Human physiology study","volume":"109","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.amjmed.2026.09.018_bib0007","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.amjmed.2026.09.018_bib0008","first-page":"155","article-title":"Aldosterone, not only an adrenal mineralocorticoid: an updated review of its functions, mechanisms, biosynthesis, hormone system and regulation in multiple organs and tissues","volume":"77","author":"Pang","year":"2026","journal-title":"J Physiol Pharmacol"},{"issue":"12","key":"10.1016\/j.amjmed.2026.09.018_bib0009","first-page":"1808","article-title":"Revising the roles of aldosterone in vascular physiology and pathophysiology: from electocortin to baxdrostat","volume":"39","author":"Feldman","year":"2023","journal-title":"Can J Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2026.09.018_bib0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of Baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.amjmed.2026.09.018_bib0011","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of Baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"issue":"10532","key":"10.1016\/j.amjmed.2026.09.018_bib0012","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0140-6736(25)02549-8","article-title":"Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjmed.2026.09.018_bib0013","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1681\/ASN.0000000849","article-title":"Efficacy and safety of Baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Dwyer","year":"2026","journal-title":"J Am Soc Nephrol"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326006819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326006819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:06:26Z","timestamp":1792213586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326006819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":13,"alternative-id":["S0002934326006819"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.09.018","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new class of drugs approved in the United States for hypertension: Aldosterone synthase inhibitors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}